The Claim
Rare myostatin gene variants associated with increased muscle mass are not significantly associated with an increased risk of hypertrophic cardiomyopathy, heart failure, or adverse changes in cardiac structure as assessed by cardiac MRI in a population of over 77,000 individuals.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare genetic variants that lead to higher muscle mass do not have a higher risk of heart enlargement, heart failure, or abnormal heart structure based on cardiac MRI scans.
See the scientific wording
Rare myostatin gene variants associated with increased muscle mass do not show a significant association with increased risk of hypertrophic cardiomyopathy, heart failure, or adverse changes in cardiac structure, as assessed by cardiac MRI in over 77,000 individuals.
When the myostatin protein is disrupted, muscles grow larger because the signal that normally limits muscle growth is turned off. This increase in muscle does not cause the heart to thicken or become damaged, because the same signal does not control heart muscle growth in the same way. The heart responds differently to the absence of myostatin, so it stays normal even when skeletal muscles become much bigger.
What the research says
1 studyPeople born with a rare gene change that makes their muscles bigger and fat less don’t have thicker hearts or more heart problems, even though they’re super muscular. So, drugs that block myostatin to build muscle probably won’t hurt the heart.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.